Insys Therapeutics Inc
The therapeutic efficacy of orally delivered THC in an Alzheimer’s mouse model
AD was treated with orally delivered THC to decrease the expression of GSK3ß protein, decrease phosphorylation of Tau protein, maintain Tau protein expression with a low dose of THC to avoid the potential psychological impairments associated with higher doses of THC.
Project period: 2015 - April 2017

Rhodes Pharmaceuticals L.P.
The Role of THC in AD, and nasal formulation for AD treatment
AD was treated using a low dose of THC alone, or in combination with melatonin, with the aim of reducing Aß expression, aggregation, maintain APP expression, and enhance mitochondrial function without the psychological impairments associated with higher doses of THC.
Project period: Dec 2015 - Jan 2018

NeuroEM Inc.
Cell phone Signal treatment for AD (clinical trial)
EMF was used to treat and prevent neurological disorders, such as Alzheimer’s disease, by utilizing an electromagnetic field emitting source that was proximal to the subject and employing a predetermined frequency for a predetermined absorption period.
Project period: Feb 2018 - Jan 2019

USF Health Intramural Zika Grant
Develop a novel vaccine against Zika virus
The Zika virus belongs to the Flaviviridae family and is spread by the Aedes mosquitoes. Currently, there is no specific treatment for the disease, and no vaccine has been approved. In order to combat the disease, a novel peptide sensitized dendritic cell vaccine was developed.